Cargando…

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab

Membranous Nephropathy (MN) is an autoimmune disease associated with antibodies against podocyte proteins: M-type phospholipase A2 receptor (PLA2R1) or thrombospondin type-1 domain-containing 7A (THSD7A) in 70 and 3% of patients, respectively. Antibody titer is correlated with disease activity: risi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyer-Suavet, Sonia, Andreani, Marine, Lateb, Maël, Savenkoff, Benjamin, Brglez, Vesna, Benzaken, Sylvia, Bernard, Ghislaine, Nachman, Patrick H., Esnault, Vincent, Seitz-Polski, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970431/ https://www.ncbi.nlm.nih.gov/pubmed/31998325 http://dx.doi.org/10.3389/fimmu.2019.03069

Ejemplares similares

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses
por: Cremoni, Marion, et al.
Publicado: (2020)

Complement Pathways in Membranous Nephropathy: Complex and Multifactorial
por: Brglez, Vesna, et al.
Publicado: (2020)

Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial
por: Brglez, Vesna, et al.
Publicado: (2020)

Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation
por: Lateb, Maël, et al.
Publicado: (2019)

Humoral and Cellular Response of Frontline Health Care Workers Infected by SARS-CoV-2 in Nice, France: A Prospective Single-Center Cohort Study
por: Cremoni, Marion, et al.
Publicado: (2021)

Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients
por: Ruetsch, Caroline, et al.
Publicado: (2021)

Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus
por: Wincup, Chris, et al.
Publicado: (2022)

Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders
por: Lebrun, Christine, et al.
Publicado: (2018)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Air pollution exposure induces a decrease in type II interferon response: A paired cohort study
por: Allouche, Jonathan, et al.
Publicado: (2022)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France
por: Graça, Daisy, et al.
Publicado: (2023)

Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022)

Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

Low baseline IFN-γ response could predict hospitalization in COVID-19 patients
por: Cremoni, Marion, et al.
Publicado: (2022)

Proteinuria as a Biomarker for COVID-19 Severity
por: Ouahmi, Hajar, et al.
Publicado: (2021)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

Membranous Nephropathy After Exposure to Immune Checkpoint Inhibitors
por: Benyahia, Rayane, et al.
Publicado: (2023)

Rituximab
por: Tridente, Giuseppe
Publicado: (2013)

Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy
por: Cheong, Jamie, et al.
Publicado: (2018)

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort
por: Gao, Shuang, et al.
Publicado: (2021)

Rituximab in Patients With Primary Membranous Nephropathy With High Immunologic Risk
por: Naik, Sachin, et al.
Publicado: (2023)

The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023)

Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies
por: Re, Daniel, et al.
Publicado: (2022)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

The efficacy of rituximab in adult frequently relapsing minimal change disease
por: King, Catherine, et al.
Publicado: (2017)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
por: Leonard, John P., et al.
Publicado: (2019)

COVİD-19 infection in a membranous nephropathy patient treated with rituximab
por: Elcioglu, Omer Celal, et al.
Publicado: (2020)

Treatment of membranous nephropathy with crescent nephritis by rituximab: A case report
por: Zhang, Fan, et al.
Publicado: (2022)

Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
por: Zhong, Hongzhen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_02pr9kseuvl4ecda6f0rgkm901